Accepted for Publication: May 1, 2014.
Published Online: July 21, 2014. doi:10.1001/jamaneurol.2014.1428.
Study concept and design: Peskind, Li, Raskind, Montine.
Acquisition, analysis, or interpretation of data: Peskind, Li, Shofer, Millard, Leverenz, Yu, Quinn, Galasko.
Drafting of the manuscript: Peskind, Li, Shofer, Millard, Galasko, Montine.
Critical revision of the manuscript for important intellectual content: Peskind, Leverenz, Yu, Raskind, Quinn, Galasko.
Statistical analysis: Li, Shofer, Millard.
Obtained funding: Peskind, Raskind, Quinn, Galasko, Montine.
Study supervision: Li, Leverenz.
Conflict of Interest Disclosures: Dr Leverenz serves as a consultant for Boehringer Ingelheim, Citigroup, Navidea Biopharmaceuticals, and Piramal Health Care. Dr Galasko serves as the editor of Alzheimer’s Research & Therapy; serves on data safety monitoring boards for Elan Pharmaceuticals Inc, Janssen, and Balance Pharmaceuticals; and is a consultant for Elan Pharmaceuticals Inc and Genentech Inc. He receives research support from the National Institutes of Health, the Michael J. Fox Foundation, and the Alzheimer’s Drug Discovery Foundation. No other disclosures were reported.
Funding/Support: This work was generously supported by the National Institutes of Health grants P50AG05136, P30AG008017, and P50AG005131 and the Nancy and Buster Alvord Endowment.
Role of the Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank Kathleen Montine, PhD (School of Medicine, University of Washington), for editorial assistance. There was no financial compensation.